Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in Europe.

ABSTRACT:

Objective

This study aimed to describe real-world patient and physician characteristics, rearranged during transfection (RET) mutation testing and results, treatment patterns, and patient-reported outcomes (PROs) in advanced or metastatic medullary thyroid cancer (aMTC) across five populous European countries.

Methods

Cross-sectional physician and patient surveys were used to collect quantitative and qualitative data in France, Germany, Italy, Spain, and the UK from July to December 2020, prior to the introduction of selective RET inhibitors in Europe. Physicians completed patient record forms and a survey about their specialty and practice site. Patients were asked to provide PRO data using four validated instruments, including the EuroQol 5 Dimension (EQ-5D) questionnaire.

SUBMITTER: Segall G 

PROVIDER: S-EPMC10895329 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature